What is the Origin of Prostate-Specific Antigen Velocity?

This concept originated in urology and oncology as a refinement of the standard PSA test, recognizing that the speed of change in a biomarker can be more clinically significant than its absolute level. The application in hormonal health is critical because testosterone can influence prostate volume and PSA production. PSAV helps clinicians differentiate between benign prostate growth and potentially malignant changes.

What is the Mechanism of Prostate-Specific Antigen Velocity?

The calculation requires at least three PSA measurements taken over a minimum period, typically 18 to 24 months, to establish a trend. A rapid increase in PSA velocity, often defined as a rise greater than 0.75 ng/mL per year, may trigger further diagnostic evaluation. In the context of hormone therapy, PSAV provides a quantitative safety benchmark, allowing for the continuation of therapy while closely monitoring prostate health.

Prostate-Specific Antigen Velocity ∞ Area

Prostate-Specific Antigen Velocity

Meaning

Prostate-Specific Antigen Velocity (PSAV) is a clinical metric that measures the rate of change in a patient’s serum Prostate-Specific Antigen (PSA) concentration over time, rather than relying solely on a single, absolute PSA value. This rate of increase is a more sensitive indicator for identifying men who may be at higher risk for aggressive prostate cancer. Monitoring PSAV is a key component of a comprehensive health surveillance protocol in men, especially those undergoing testosterone replacement therapy.